• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Tennis

Maria Sharapova Just Admitted She Failed a Drug Test at the Australian Open

By
Benjamin Snyder
Benjamin Snyder
Managing Editor
Down Arrow Button Icon
By
Benjamin Snyder
Benjamin Snyder
Managing Editor
Down Arrow Button Icon
March 7, 2016, 3:31 PM ET
Tennis player Maria Sharapova addresses the media at The LA Hotel Downtown on March 7, 2016 in Los Angeles, California. Sharapova, a five-time major champion, is currently the 7th ranked player on the WTA tour. Sharapova, withdrew from this week’s BNP Paribas Open at Indian Wells due to injury.
Photograph by Kevork Djansezian — Getty Images

In a press conference, Maria Sharapova, the five-time major champion, announced she failed a drug test at the 2016 Australian Open.

Sharapova, 28, who lost to Serena Williams in the quarterfinals, was widely expected to be announcing her retirement. But instead, she delivered the shocking news that she had been taking a drug, called meldonium, since 2006. The drug was recently placed on the International Tennis Federation’s list of banned substances in 2016, said the Russian.

“I failed the test and take full responsibility for that,” said Sharapova, who said she’s been using the substance for health reasons.

“I had been taking this medicine for the past 10 years,” she added, “but on 1 January this became a prohibited substance which I did not know.”

Meldonium is listed in a document on the ITF’s website as a “metabolic modulator.”

“I received an email on 22 December from Wada [World Anti-Doping Agency] about the changes happening to the banned list and you can see prohibited items,” Sharapova added during the press conference, “and I didn’t click on that link.”

Sharapova, who is currently ranked No.7 in the world, has been as high as No.1. Off-court, Sharapova has focused on businesses by collecting millions in endorsement deals with brands such as Nike. In 2012, Sharapova started her own candy business called Sugarpova.

“As meldonium is a non-specified substance under the WADA (and, therefore, TADP) list of Prohibited Substances and Prohibited Methods, Ms Sharapova will be provisionally suspended with effect from 12 March, pending determination of the case,” according to ITF in a written statement.

It is unclear how the announcement will effect her endorsement deals. Fortune has reached out to Nike.

Last year, Fortune examined Sharapova’s marketability over rival Williams tied to the U.S. Open major tennis tournament.

“I have let my fans down, and let the sport down that I have been playing since age of four that I love so deeply,” she said. “I know that with this I face consequences and I don’t want to end my career this way. I really hope to be given another chance to play this game.”

About the Author
By Benjamin SnyderManaging Editor
LinkedIn iconTwitter icon

Benjamin Snyder is Fortune's managing editor, leading operations for the newsroom.

Prior to rejoining Fortune, he was a managing editor at Business Insider and has worked as an editor for Bloomberg, LinkedIn and CNBC, covering leadership stories, sports business, careers and business news. He started his career as a breaking news reporter at Fortune in 2014.

See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.